Genentech, part of the Roche Group (SIX:RO (SIX:ROG) (OTCQX:RHHBY), revealed on Thursday that the US Food and Drug Administration (FDA) has approved a Tecentriq (atezolizumab) combination therapy for people with advanced melanoma.
Tecentriq plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) was approved for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
The approval was based on results from the Phase III IMspire150 study, which showed that the addition of Tecentriq to Cotellic and Zelboraf helped people live longer without their disease worsening or death (progression-free survival), compared to placebo plus Cotellic and Zelboraf.
The supplemental Biologics License Application (sBLA) for Tecentriq was granted under Priority Review.
Viking Therapeutics plans offerings of common stock and convertible senior notes
Astellas doses first patient in Phase 3 lung cancer study
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
Ondine Biomedical deployssteriwave across five Southern Ontario hospitals
Ionis reports positive Phase 3 sefaxersen data in IgA nephropathy
X-Chem and Relay Therapeutics collaborate on Phase 3 milestone
BoomRay enters exclusive radioligand therapy asset global license agreement with Novartis
AstronauTx receives funding to explore sleep-based approaches for Parkinson's disease
AbbVie secures EU approval for RINVOQ in polyarticular juvenile idiopathic arthritis
Genentech reports positive Phase II results for enicepatide in type 2 diabetes
Pharming reports positive Phase II data for leniolisib in primary immunodeficiencies
Insmed's ARIKAYCE sNDA granted priority review by FDA
Precigen announces FDA platform technology designation for AdenoVerse
Enhertu recommended for EU approval in early HER2-positive breast cancer
PureTech receives FDA Fast Track designation for LYT-200 in HR-MDS